Back to Search
Start Over
Characterization of a new dual-targeting fully human antibody with potent antitumor activity against nasopharyngeal carcinoma.
- Source :
- Biological Chemistry; Aug2015, Vol. 396 Issue 8, p917-921, 5p, 1 Chart, 2 Graphs
- Publication Year :
- 2015
-
Abstract
- Despite the effectiveness of the anti-EGFR chimeric antibody (mAb), cetuximab, in treating nasopharyngeal carcinoma (NPC), its efficacy remains variable and often modest. In this study, a full human dual targeted anti-EGFR/HER3 antibody, CA1182, was generated from phage display library. CA1182 was as effective as cetuximab or trastuzumab in inhabiting phosphorylation of EGFR or HER2, but it exhibited as much more potent than cetuximab or trastuzumab. Moreover, our studies showed that CA1182 was significantly more effective than cetuximab in prolonging the survival of severe combined immune deficient mice bearing human NPC, suggesting that it might be a promising therapeutic agent for NPC. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14316730
- Volume :
- 396
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- Biological Chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 103638212
- Full Text :
- https://doi.org/10.1515/hsz-2014-0236